| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | -0.43 | 1e-11 |
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | 0.25 | 6e-11 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.23 | 3e-10 |
| mRNA | bendamustine | CTRPv2 | pan-cancer | AAC | 0.24 | 1e-08 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | -0.23 | 2e-08 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | -0.22 | 3e-08 |
| mRNA | Bryostatin 1 | GDSC1000 | pan-cancer | AAC | -0.24 | 3e-08 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | -0.28 | 4e-08 |
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | -0.3 | 7e-08 |
| mRNA | CIL41 | CTRPv2 | pan-cancer | AAC | 0.28 | 8e-08 |